

Remarks

Remarks are arranged in numerical or subject headings as set forth in the office action.

Claim Rejections – 35 USC §103

Claims 1-4, 7, and 9-11 are rejected under 35 USC 103(a) as being unpatentable over Weintraub et al.

Claims 1-4, and 7 are canceled.

Claim 9 is amended as shown in Listing of Claims. Weintraub et al fail to teach the method for reduction of plasma glucose concentrations in diseases, disorders or conditions in human or non-human mammals as specified in amended claim 9.

Weintraub et al further fail to teach the use of the composition consisting of the two agents.

In fact, Weintraub et al specifically teach that gemfibrozil is administered to type IV HLP patients and teaching away from the claimed invention.

Applicants submit that amended claim 9 overcomes the rejection under 35 USC 103.

New claims 12 is dependent from claim 9. New claim 13 is dependent from claim 12. Claim 11 is now dependent from the claim 13. New claim 14 is dependent from claim 9. Limitations of claim 9 are read into these claims. Aforementioned observations are equally applicable to these claims.

Claim Rejections -35 USC §112, First paragraph and Second paragraph


Luo, Jian
Application No.: 10/507,382
Case No.: MGC020325

Applicants submit that the amendments overcome the rejections under 35 USC 112 first and second paragraphs.

Conclusion

In view of the foregoing, allowance of the pending claims is respectfully requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'Jian Luo', written over the printed name and address.

Jian Luo
992 Ventura Ave.
Albany, Ca 94706
(415)-987-8168

Date: August 30, 2009